- advertisement -

Three Unsuccessful Trials

Discussion in 'Research' started by joshualevy, Oct 16, 2014.

  1. joshualevy

    joshualevy Approved members

    Joined:
    Dec 30, 2008
    Messages:
    646
    This blog posting summarizes several clinical trials aimed at curing type-1 diabetes which have failed. These are never fun, happy blog postings, but they are important. One of the big problems with trying to understand research based on mass media reporting is that failures are rarely covered at all. The soundtrack for this posting is "Down" by Melissa Lambert:
    http://grooveshark.com/#!/s/Down/4BHhwn


    Sitagliptin and Lansoprazole Unsuccessful in Phase-II Trial


    This was a combination therapy. The researchers were attempting to combine a drug to stop the autoimmune attack and another drug to trigger beta cell growth. Both drugs were approved for other purposes, and commonly used. Unfortunately, it didn't work. Summary from abstract:


    At 12 months, the mean change in C-peptide area under curve was −229 pmol/L for the treatment group and −253 pmol/L for the placebo group; this difference was not significant (p=0·77).


    Abstract: http://www.sciencedirect.com/science/article/pii/S2213858714701159
    Blog at start of trial: http://cureresearch4type1diabetes.blogspot.com/2010/08/possible-cures-for-type-1-in-news-mid.html


    Pioglitazone Unsuccessful in Phase-I Trial


    Pioglitazone has been approved for use in type-2 diabetes for over 10 years. It is part of a larger drug family called thiazolidinediones which have been shown to preserve beta cells in animals with type-1 diabetes, and to reduce death of beta cells in petri dishes. It was being tested as a honeymoon cure, but did not pan out:


    Conclusion: In this pilot study, pioglitazone did not preserve β cell function when compared to placebo.


    Article: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3890222/
    Previous blogging: http://cureresearch4type1diabetes.blogspot.com/search/label/Pioglitazone


    Stop Covering Lisofylline


    As far as I can tell, no one has done human trials of this treatment for over two years, so I'm going to stop considering it as a possible cure, unless something new comes to light. Lisofylline is an anti-inflammatory.


    Previous coverage (one blog posting) is here:
    http://cureresearch4type1diabetes.blogspot.com/search/label/Lisofylline




    [FONT=Georgia, Times New Roman, serif]Joshua Levy[/FONT]
    http://cureresearch4type1diabetes.blogspot.com
    publicjoshualevy at gmail dot com
    All the views expressed here are those of Joshua Levy, and nothing here is official JDRF, JDCA, or Tidepool news, views, policies or opinions. My daughter has type-1 diabetes and participates in clinical trials, which might be discussed here. My blog contains a more complete non-conflict of interest statement. Thanks to everyone who helps with the blog.
     
  2. chalke43

    chalke43 Approved members

    Joined:
    Oct 31, 2013
    Messages:
    20
    Joshua,

    I was wondering what, if anything, you know about Pfizer's study drug PF-063426744? I saw one brief mention of it in one of your posts, but there isn't much info out there it seems. One of our local endos is recruiting patients for a study. I have found that they are also doing studies on this drug in relation to MS, and the trial information says the drug is an antibody that binds to and inhibits a receptor that is potentially involved in MS, ideally slowing down the progression of the disease. However, I can't find any similar information indicating how they hope the drug would work in relation to T1D. Thanks for all that you do keeping us updated on the research out there.
     
  3. joshualevy

    joshualevy Approved members

    Joined:
    Dec 30, 2008
    Messages:
    646
    I'll look into PF-06342674, (only one 4 at the end) and put something on the blog. But I"m a little backed up at the moment, and it might take a few weeks. --Joshua
     

Share This Page

- advertisement -

  1. This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
    By continuing to use this site, you are consenting to our use of cookies.
    Dismiss Notice